文献速递瓣膜外科

主动脉瓣狭窄合并二尖瓣反流患者的经导管主动脉瓣置换术

Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Mitral Regurgitation.
PubMed 文献 · Ann Thorac Surg · 2017-09-29

本研究基于美国TVT注册研究2012–2013年11104例TAVR患者,评估合并二尖瓣反流(MR)对临床结局的影响及TAVR后MR变化。结果显示中重度MR与1年死亡或心衰再住院风险增加相关,但多数患者TAVR后MR早期改善,未改善者风险更高。

要点

  • 中重度MR在TAVR患者中常见,与1年死亡或心衰再住院风险增加相关。
  • TAVR后多数中重度MR早期改善,改善者死亡率与心衰再住院率更低。
  • MR未改善的少数患者风险较高,可能需监测和针对性干预。

核心结论

  • 重度主动脉瓣狭窄合并中重度MR接受TAVR与死亡或心衰再住院风险增加相关。
  • 风险增加可能归因于少数MR未改善的患者。

研究设计与样本

  • 基于美国TVT注册研究2012年1月3日至2013年12月31日接受TAVR的患者,共11104例,长期结局来自CMS数据。

主要发现

  • 11104例中,中度MR 3481例(31.3%),重度MR 605例(5.5%)。
  • 1年死亡率在无、轻度、中度、重度MR组分别为21.0%、21.5%、26.3%、28.0%(p < 0.0001)。
  • 1年心衰再住院率在无、轻度、中度、重度MR组分别为13.9%、15.8%、20.3%、23.4%(p < 0.0001)。
  • 校正基线差异后,中度MR的1年死亡或心衰再住院HR为1.16(95% CI 0.99–1.35),重度MR为1.21(95% CI 0.97–1.50)。
  • TAVR后MR早期改善≥1级在重度MR中占79%,中度MR中占66%;改善者死亡率(p = 0.022)和心衰再住院率(p < 0.001)更低。

临床怎么用

  • 对TAVR合并中重度MR患者应关注MR是否改善,未改善者可能需加强监测和针对性干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients undergoing transcatheter aortic valve replacement (TAVR) for aortic stenosis also have significant mitral regurgitation (MR). We sought to understand the association of concomitant MR with TAVR clinical outcomes, as well changes in MR after TAVR. METHODS: Patients who underwent TAVR in the US Transcatheter Valve Therapy Registry from January 3, 2012, to December 31, 2013, were studied, with longer-term clinical outcomes from Center for Medicare Services data. RESULTS: Of 11,104 patients, 3,481 (31.3%) had moderate MR, and 605 (5.5%) had severe MR. At 1 year, mortality was 21.0%, 21.5%, 26.3%, and 28.0% (p < 0.0001) and heart failure (HF) rehospitalization was 13.9%, 15.8%, 20.3%, and 23.4% (p < 0.0001) in the no, mild, moderate, and severe MR patients, respectively. After adjustment for baseline differences, significant MR was associated with increased risk of 1-year mortality or HF rehospitalization, with a HR of 1.16 (95% CI, 0.99 to 1.35) for moderate MR and 1.21 (95% CI, 0.97 to 1.50) for severe MR, compared with no MR. MR improved early after TAVR grade ≥ 1 in 79% of the severe MR patients and 66% of the moderate MR patients. Patients whose baseline moderate or severe MR improved had lower mortality (p = 0.022) and HF rehospitalization (p < 0.001) compared with patients whose MR did not improve. CONCLUSIONS: Moderate or severe MR accompanying severe AS treated with TAVR is associated with increased mortality or HF rehospitalization. This increased risk may be attributable to the minority of patients whose MR does not improve, suggesting a potential role for surveillance and targeted intervention for those patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mavromatis K, Thourani VH, Stebbins A, et al. Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Mitral Regurgitation. Ann Thorac Surg. 2017. PMID: 28965619. doi:10.1016/j.athoracsur.2017.05.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。